- Lynestrenol
-
- $0.00 / 1g
-
2024-09-20
- CAS:52-76-6
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Lynestrenol
-
- $0.00 / 1g
-
2024-09-18
- CAS:52-76-6
- Min. Order: 1g
- Purity: 98.0%-102.0%;BP
- Supply Ability: 100 KGS
- Lynestrenol
-
- $10.00 / 1kg
-
2024-03-08
- CAS:52-76-6
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000kg
|
| Lynestrenol Basic information |
Product Name: | Lynestrenol | Synonyms: | 4-ESTREN-17-ALPHA-ETHYNYL-17-BETA-OL;4-ESTREN-17A-ETHINYL-17BETA-OL;19-nor-17-alpha-pregn-4-en-20-yn-17-l;ETHINYLESTRENOL;LYNOESTRENOL;LYNESTRENOL;(17-alpha)-19-norpregn-4-en-20-yn-17-ol;17-alpha-ethinyl-17-beta-hydroxyestr-4-ene | CAS: | 52-76-6 | MF: | C20H28O | MW: | 284.44 | EINECS: | 200-151-4 | Product Categories: | Steroids;Hormone;Intracellular receptor | Mol File: | 52-76-6.mol | |
| Lynestrenol Chemical Properties |
Melting point | 158°C | alpha | D -13° (chloroform) | Boiling point | 366.92°C (rough estimate) | density | 1.0083 (rough estimate) | refractive index | 1.4500 (estimate) | storage temp. | 2-8°C | solubility | Practically insoluble in water, soluble in acetone and in ethanol (96 per cent). | form | Solid | pka | 13.12±0.40(Predicted) | color | Crystals from MeOH | Merck | 14,5629 | CAS DataBase Reference | 52-76-6 | EPA Substance Registry System | Lynestrenol (52-76-6) |
| Lynestrenol Usage And Synthesis |
Chemical Properties | White or almost white, crystalline powder. | Uses | Progestogen;Antioestrogen | Uses | Lynestrenol is an orally available progestogen hormone used in contraception to avoid hereditary angiodema as well as in treatment of ischemic stroke. | Definition | ChEBI: Lynestrenol is a steroid. It derives from a hydride of an estrane. | Brand name | Anacycline 101;Anacylin 101;Anacylin 28;Ancylin;Athilyn;Endometril;Exluton (a);Fysiognens;Fysionorm;Gestrol;Lindiol 2.5;Lyn_ratiopharm;Lyn_ratiophram_sequenz;Lyndeol;Lyndile tt;Lyndiol e.;Lyndiolett;Lynoenstrenol;Lyn-ratiopharm;Mini pregnon;Minifol;Minilyn;Neo lyndiol;Neo-lindiol;Neo-lynobol;Nonovulet;Noracyclin 22;Normophasic;Novostat;Org 485-50;Orgaluton;Orgametrol;Ovamezzo;Ovanone;Ovanon-e;Ovariostat;Ovoresta micro;Ovostat-28;Ovostat-micro;Phasicon;Physiostat;Physistat;Pregnon-28;Restovar. | World Health Organization (WHO) | Lynestrenol, a synthetic progestogen, was introduced in the early
1960s as a component in oral contraceptive preparations. In 1967, as a result of
new regulations required by the United States Food and Drug Administration,
lynestrenol was submitted to long-term toxicity studies and by the early 1970s it
was shown to be associated with an increased incidence of mammary tumours in
beagle bitches which led to its withdrawal by at least one regulatory authority.
Subsequently the validity of the beagle bitch model as a predictor of
carcinogenicity of steroid contraceptives has been contested by many national
regulatory authorities and lynestrenol remains available in some countries for
contraceptive and other purposes.
(Reference: (WHODI) WHO Drug Information, 1-3, 5-7, 1984) | Safety Profile | An experimental teratogen.Experimental reproductive effects. Human reproductiveeffects by ingestion and implant routes: menstrual cyclechanges or disorders, female fertility index, other fertilitychanges and effects on females. Questionable carcinoge |
| Lynestrenol Preparation Products And Raw materials |
|